Merck Earnings Beat Estimates; More Acquisitions on Tap
Drug giant Merck reported mixed first-quarter 2016 results before markets opened Thursday morning.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Drug giant Merck & Co. Inc. (NYSE: MRK) reported first-quarter 2016 results before markets opened Thursday. The company posted adjusted diluted earnings per share (EPS) of $0.89 and revenues of $9.31 billion. In the same period a year ago, Merck reported EPS of $0.85 on revenues of $9.43 billion. First-quarter results also compare to the Thomson Reuters consensus estimates for EPS of $0.85 and $9.46 billion in revenues.
Pharmaceutical sales were down 2% year over year; however, excluding currency exchange effects, sales were up 2%. Net income on a GAAP basis totaled $1.13 billion while non-GAAP net income totaled $2.49 billion. Non-GAAP net income excludes the impacts of $1.1 billion in expenses for the amortization of intangible assets related to acquisitions, $24 million related to the 2015 acquisition of Cubist Pharmaceuticals and $252 million in impairment charges on product intangibles.
In its financial outlook statement, Merck narrowed and raised the top end of its full-year adjusted EPS from a prior range of $3.60 to $3.75 to a new range of $3.65 to $3.77. The company also said its full-year revenues are expected to fall in a range of $39.0 billion to $40.2 billion, including an estimated 2% negative impact from currency exchange rates.
[recirclink id=330032]
Chairman and CEO Kenneth C. Frazier said:
Our first quarter’s performance sets us on a good course for the year. We remain focused on advancing our pipeline and driving the commercial success of our key launches and inline medicines and vaccines. Business development is a top priority, and we are actively pursuing the best external science through licensing or bolt-on acquisitions to bolster our pipeline and grow our company.
Since the beginning of the year, Merck’s stock is up 3.8%, but down about 9% over the past 12 months.
Shares of Merck’s stock traded up nearly 1% in Thursday’s premarket, at $55.30 in a 52-week range of $45.69 to $61.70. Thomson Reuters had a consensus analyst price target of $61.47 before the earnings report.
Contact [email protected] for any questions or corrections.
Paul Ausick has been writing for 247Wallst.com for more than a decade. He has written extensively on investing in the energy, defense, and technology sectors. In a previous life, he wrote technical documentation and managed a marketing communications group in Silicon Valley.
He has a bachelor's degree in English from the University of Chicago and now lives in Montana, where he fishes for trout in the summer and stays inside during the winter.
